Compare CNXN & STOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CNXN | STOK |
|---|---|---|
| Founded | 1982 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.0B |
| IPO Year | 1997 | 2019 |
| Metric | CNXN | STOK |
|---|---|---|
| Price | $80.79 | $32.96 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $39.20 |
| AVG Volume (30 Days) | 142.7K | ★ 593.3K |
| Earning Date | 04-29-2026 | 05-08-2026 |
| Dividend Yield | ★ 1.26% | N/A |
| EPS Growth | N/A | ★ 92.73 |
| EPS | ★ 1.99 | N/A |
| Revenue | N/A | ★ $184,420,000.00 |
| Revenue This Year | $6.24 | N/A |
| Revenue Next Year | $4.39 | $77.49 |
| P/E Ratio | $41.64 | ★ N/A |
| Revenue Growth | N/A | ★ 404.50 |
| 52 Week Low | $54.97 | $13.17 |
| 52 Week High | $88.31 | $40.22 |
| Indicator | CNXN | STOK |
|---|---|---|
| Relative Strength Index (RSI) | 51.58 | 62.67 |
| Support Level | $56.57 | $32.70 |
| Resistance Level | $88.31 | $34.83 |
| Average True Range (ATR) | 3.13 | 1.58 |
| MACD | -0.48 | 0.42 |
| Stochastic Oscillator | 14.47 | 95.51 |
PC Connection Inc is a provider of information technology solutions. It provides products such as computer systems, software and peripheral equipment, networking communications, and other products and accessories that company purchase from manufacturers and distributors. The company also offers services involving design, configuration, and implementation of IT solutions. It conducts business operations through three business segments namely Connection Business Solutions, Connection Enterprise Solutions, and Connection Public Sector Solutions. The company generates maximum revenue Connection Enterprise Solutions segment.
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.